Lantheus Holdings to Present at the 4th Annual Evercore ISI HealthCONx Conference
Lantheus Holdings, a leader in imaging diagnostics and therapeutics, will have its CFO, Bob Marshall, present at the 4th Annual Evercore ISI HealthCONx Conference on November 30, 2021, at 1:00 p.m. ET. Interested parties can access a live webcast through the Investors section of their website, with a replay available for 30 days post-event. The company focuses on innovative diagnostic solutions and has a portfolio that includes products like DEFINITY, PYLARIFY, and RELISTOR.
- None.
- None.
NORTH BILLERICA, Mass., Nov. 16, 2021 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (NASDAQ: LNTH) (Lantheus), an established leader and fully integrated provider committed to innovative imaging diagnostics, targeted therapeutics and artificial intelligence solutions to find, fight and follow serious medical conditions, today announced Bob Marshall, Chief Financial Officer and Treasurer, will present at the 4th Annual Evercore ISI HealthCONx Conference at 1:00 p.m. ET on Tuesday, November 30.
To access a live webcast of the presentation, please visit the Investors section of the Company’s website at www.lantheus.com. A replay of the webcast will be available on the Company’s website for 30 days following the live presentation.
About Lantheus Holdings, Inc.
Lantheus Holdings, Inc. is the parent company of Lantheus Medical Imaging, Inc., Progenics Pharmaceuticals, Inc. and EXINI Diagnostics AB and an established leader and fully integrated provider committed to innovative imaging diagnostics, targeted therapeutics and artificial intelligence solutions to Find Fight and Follow® serious medical conditions. Lantheus provides a broad portfolio of products, including the echocardiography agent DEFINITY® Vial for (Perflutren Lipid Microsphere) Injectable Suspension; PYLARIFY®, a PSMA PET imaging agent for the detection of suspected recurrent or metastatic prostate cancer; TechneLite® (Technetium Tc99m Generator), a technetium-based generator that provides the essential medical isotope used in nuclear medicine procedures; AZEDRA® for the treatment of certain rare neuroendocrine tumors; and RELISTOR® for the treatment of opioid-induced constipation, which is partnered with Bausch Health Companies, Inc. The Company is headquartered in North Billerica, Massachusetts with offices in New Jersey, Canada and Sweden. For more information, visit www.lantheus.com.
Contacts:
Mark Kinarney
Senior Director, Investor Relations
978-671-8842
ir@lantheus.com
Melissa Downs
Director, Corporate Communications
646-975-2533
media@lantheus.com
FAQ
What time is the Lantheus Holdings presentation at the Evercore ISI HealthCONx Conference?
Where can I watch the Lantheus Holdings presentation live?
How long will the Lantheus Holdings presentation be available for replay?
What products does Lantheus Holdings offer?
What is the stock symbol for Lantheus Holdings?
